BioMarin develops medicines for people living with genetically defined rare diseases. With eight approved therapies and a robust pipeline, the company translates genetic discoveries into treatments that address the underlying causes of complex conditions. Founded in 1997, BioMarin operates in approximately 80 countries worldwide, combining scientific rigour with a patient centred approach. Each medicine begins with deep engagement in patient communities, listening to families who live with these conditions. BioMarin pursues therapies that make a meaningful difference in daily life, addressing disease mechanisms at their source. The company manufactures products in facilities across Northern California and Ireland.
3221
Team Members
1997
Founded
Biotechnology
Sector
Hybrid
Work Environment
A world where genetically defined rare diseases no longer limit lives, where every patient has access to transformative treatments that address the root cause of their condition and unlock their full potential for health and wellbeing.
Translates the promise of genetic discovery into medicines that make a profound impact on the life of each patient.